Search International and National Patent Collections

1. (WO2018133545) GENE ENGINEERING ARGININE DEIMINASE REFORMED THROUGH SITE DIRECTED MUTAGENESIS

Pub. No.:    WO/2018/133545    International Application No.:    PCT/CN2017/113162
Publication Date: Fri Jul 27 01:59:59 CEST 2018 International Filing Date: Tue Nov 28 00:59:59 CET 2017
IPC: C12N 9/78
C12N 9/00
C12N 15/55
C12N 15/70
C12N 15/00
Applicants: JIANGNAN UNIVERSITY
江南大学
Inventors: ZHANG, Tao
张涛
JIANG, Bo
江波
JIANG, Hangyu
蒋航宇
MU, Wanmeng
沐万孟
MIAO, Ming
缪铭
Title: GENE ENGINEERING ARGININE DEIMINASE REFORMED THROUGH SITE DIRECTED MUTAGENESIS
Abstract:
A strain of gene engineering arginine deiminase reformed through site directed mutagenesis, relating to the technical field of gene engineering. The amino acid sequence is SEQ ID No.1, and the 264 site glycine in the amino acid sequence of the arginine deiminase reformed through site directed mutagenesis mutates into proline relative to the amino acid sequence of the natural arginine deiminase. Compared to a wild enzyme, the effective pH action range of the mutant arginine deiminease is expanded to a certain degree, and in particularly, the mutant arginine deiminease has good enzyme activity at the physiological pH value of 7.4. The mutant enzyme has the high stability under the pH value of 5.5-7.5 along with the broadening of the effective pH action range. Therefore, the problems of low enzyme activity and short half-life in vivo under physiological conditions of the clinical applications of the arginine deiminase in tumor treatment are solved, and good conditions are created for the application of the arginine deiminase and the coding gene thereof in clinical treatment.